>latest-news

New CMO Brings Expertise To Genascence's Gene Therapy Pipeline

Genascence names Dr. Jeymi Tambiah as CMO to advance gene therapies for musculoskeletal diseases.

Breaking News

  • Oct 30, 2024

  • Simantini Singh Deo

New CMO Brings Expertise To Genascence's Gene Therapy Pipeline

Genascence Corporation, a biotech company focused on pioneering gene therapies for common musculoskeletal diseases, has today assigned Dr. Jeymi Tambiah as its new Chief Medical Officer. Dr. Tambiah, MBChB, FRCS, MS, FAPCR, MFPM(Dis), is a seasoned physician-scientist who brings over 15 years of experience in the biopharma industry, including leadership in medical affairs, clinical development, and drug development programs. His expertise in translational medicine, commercialisation and health outcomes research will be vitally important to Genascence as it advances its therapeutic pipeline.


Before joining Genascence, Dr. Tambiah served as Senior Vice President of Clinical Development and External Innovation at Biosplice Therapeutics, where he led clinical development and formed strategic partnerships for research in oncology, arthritis, and neurodegenerative diseases. He also held various leadership roles at UCB Pharma, where he successfully launched certolizumab pegol, a TNF inhibitor, across Europe and the U.S. for multiple immunology indications. Before transitioning to industry, Dr. Tambiah trained in cardiothoracic surgery at London’s Guys’ and St. Thomas’ Hospitals.


"Genascence is a company that is transforming how we treat debilitating musculoskeletal diseases like osteoarthritis by pioneering the development of gene therapy. I. I am thrilled to join this outstanding team under Tom's leadership and apply my knowledge and experience to advance our clinical program to bring potentially curative therapies to patients in desperate need of better treatments," said Dr Tambiah. 


An active contributor to the osteoarthritis research community, Dr. Tambiah has received numerous research awards, holds committee roles, and frequently presents at global conferences. He also serves as the North American representative for the UK Faculty of Pharmaceutical Medicine, where he supports physician education and mentorship in drug development. Dr. Tambiah earned his medical degree from the University of Manchester, a doctorate in vascular biology from Imperial College London, and a BSc in medical science from the University of St. Andrews. He is a Fellow of the Royal College of Surgeons of both England and Edinburgh, a member by distinction of the UK Faculty of Pharmaceutical Physicians, and a Fellow of the Academy of Physicians in Clinical Research.


Thomas Chalberg, Ph.D., founder and CEO of Genascence, said in a statement, “Jeymi is a visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in the areas of osteoarthritis, immunology, oncology, and neuroscience, and I am excited to welcome him to Genascence as our chief medical offer."


He further said, "His experience includes all phases of drug development from bench through Phase 1-4 clinical studies and building elite high-performance medical affairs teams. Jeymi's development and research expertise, particularly within the osteoarthritis research community, will be invaluable as we execute our strategy to bring gene therapy to people suffering from prevalent musculoskeletal diseases." 

Ad
Advertisement